The favorable outcome of the lawsuit by NPS Pharmaceuticals (NASDAQ:NPSP) against Teva for ANDA filing of generic Sensipar has been ruled in NPS's favor, and that removes significant risk for the company.
Brean Murray Carret & Co. said the ruling should keep the generic Sensipar off the market until 2018, when the original Sensipar patents run out.
They raised their full year 2010 and full year 2011 EPS estimates from $0.77 and $0.42 to $0.75 and $0.37.
Brean Murray Carret & Co. reiterates a "Buy" rating on NPS Pharmaceuticals Inc., which closed Monday at $7.61, gaining $0.39, or 5.4 percent. They increased their price target on NPS from $10 to $11.
Tuesday, January 11, 2011
NPS Pharmaceuticals (NASDAQ:NPSP) Gets Favorable Amgen/NPSP Ruling
Labels:
Brean Murray Carret,
NPS Pharmaceuticals
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment